The effect of alirocumab, a PCSK9 inhibitor, on the plaque volume and characteristics were evaluated in the PACMAN-AMI (Effects of the PCSK9 Antibody Alirocumab on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction) randomized trial (15). Here, PCSK9 is linked to acute myocardial infarction.